Genome editing abrogates angiogenesis in vivo

Xionggao Huang1,2,3, Guohong Zhou1,2,4, Wenyi Wu1,2,5, Yajian Duan1,2,4, Gaoen Ma1,2, Jingyuan Song1,2,6, Ru Xiao1,2, Luk Vandenberghe1,2, Feng Zhang7, Patricia A. D’Amore1,2 & Hetian Lei1,2

Angiogenesis, in which vascular endothelial growth factor receptor (VEGFR) 2 plays an essential role, is associated with a variety of human diseases including proliferative diabetic retinopathy and wet age-related macular degeneration. Here we report that a system of adeno-associated virus (AAV)-mediated clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease (Cas)9 from Streptococcus pyogenes (SpCas9) is used to deplete VEGFR2 in vascular endothelial cells (ECs), whereby the expression of SpCas9 is driven by an endothelial-specific promoter of intercellular adhesion molecule 2. We further show that recombinant AAV serotype 1 (rAAV1) transduces ECs of pathologic vessels, and that editing of genomic VEGFR2 locus using rAAV1-mediated CRISPR/Cas9 abrogates angiogenesis in the mouse models of oxygen-induced retinopathy and laser-induced choroid neovascularization. This work establishes a strong foundation for genome editing as a strategy to treat angiogenesis-associated diseases.
Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, the process by which new blood vessels grow from pre-existing vessels. Among the VEGF receptors 1, 2, and 3 (VEGFR1, 2, and 3), VEGFR2 mediates nearly all known VEGF-induced output, including microvascular permeability and neovascularization (NV). NV is critical for supporting the rapid growth of solid tumors beyond 1–2 mm³ and for tumor metastasis. Abnormal angiogenesis is also associated with a variety of other human diseases such as proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and wet age-related macular degeneration (AMD). PDR accounts for the highest incidence of acquired blindness in the working age population; ROP is a major cause of acquired blindness in children; AMD represents the leading cause of blindness in people over the age of 65 affecting 30–50 million people globally. Preventing VEGF-stimulated activation of its receptors with neutralizing VEGF antibodies (ranibizumab and bevacizumab) and the extracellular domains of VEGFR1 and 2 (alibecertin) is currently an important therapeutic approach to angiogenesis in these eye diseases but requires chronic treatment.

Although these anti-VEGF agents can reduce neo-vascular growth and lessen vascular leakage, there are still therapeutic challenges to a significant number of patients with these eye diseases.

Adeno-associated viruses (AAVs) are small viruses that are not currently known to cause any disease, and their derived vectors show promise in human gene therapy. The clustered regularly interspersed palindromic repeats (CRISPR)-associated DNA endonuclease (Cas9) in Streptococcus pyogenes (SpCas9) processes pre-crRNA transcribed from the repeat spacers into CRISPR RNAs (crRNA) and cleave invading nucleic acids on the guidance of crRNA and trans-activating crRNA (tracrRNA). A single guide RNA (sgRNA) engineered as the crRNA-tracrRNA chimeric RNA can direct sequence-specific SpCas9 cleavage of double-strand DNA containing an adjacent “NGG” protospacer-adjacent motif (PAM). This CRISPR/Cas9 system is a powerful tool for the targeted introduction of mutations into eukaryotic genomes and subsequent protein depletion.

In this study, we employed the AAV-mediated CRISPR/Cas9 system to edit genomic VEGFR2 in vivo and showed that editing of VEGFR2 abrogated angiogenesis in two mouse models of oxygen-induced retinopathy (OIR) and laser-induced choroid NV (CNV).

Results

CRISPR/Cas9-mediated depletion of VEGFR2 in vascular ECs in vitro. Recombinant AAV (rAAV) vectors are at present the leading candidates for virus-based gene therapy thanks to their broad tissue tropism, non-pathogenic nature, and low immunogenicity. In this study, we adapted a dual-AAV vector system packaging SpCas9 and SpGuide. To identify an appropriate AAV serotype that could transduce vascular endothelial cells (ECs), we replaced the GFP promoter (phSyn) in the AAV-SpGuide vector with a promoter of cytomegalovirus (CMV) (Fig. 1a). A major goal of gene therapy is the introduction of genes of interest into desired cell types. To circumvent targeting VEGFR2 in photoreceptors of eye tissues, an endothelial-specific promoter is designed to drive expression of SpCas9. Thus, we substituted the Mecp2 promoter in the AAV-pMecp2-2SpCas9 vector for an endothelial-specific promoter of intercellular adhesion molecule 2 (pICAM2) (Fig. 1b).

Recombinant adeno-associated virus serotype 1 (rAAV1) has been shown to transduce vascular ECs in high efficiency. We next examined whether rAAV1 was able to deliver the CRISPR–Cas9 into ECs. As shown in Fig. 1c, rAAV1 was able to infect human primary retinal microvascular ECs (HRECs), human primary umbilical vein ECs (HUVECs) as well as human primary retinal pigment epithelial cells (hPRPE). Subsequently, we transduced these cells with rAAV1-2SpCas9 (rAAV1-SpCas9) for testing if the ICAM2 promoter was able to drive SpCas9 expression in ECs specifically. Western blot analysis of the transduced cell lysates indicated that SpCas9 was expressed in HRECs and HUVECs, but not in hPRPE cells (Fig. 1d), demonstrating that the dual vectors of AAV-SpCas9 and AAV-SpGuide are able to specifically target genomic loci of ECs. Then, a target mouse genomic sequence named as mK22 (Fig. 1a) corresponding to the most efficient sgRNA-targeting human VEGFR2 exon 3 named as K12 among the four target sequences was cloned into the SpGuide vector.

To assess the editing efficiency of our dual-vector system in vitro, we infected C57BL/6 mouse primary brain microvascular ECs (MVECs) using rAAV1-SpCas9 with rAAV1-mK22 or rAAV1-lacZ. After 4 days post-infection, the genomic DNA was isolated for PCR. Sanger DNA sequencing results showed that there were mutations around the PAM sequence of PCR products from MVECs transduced with rAAV1-SpCas9 plus mK22 but not from those with rAAV1-SpCas9 plus lacZ (Fig. 1e), suggesting that the mK22-guided SpCas9 cleaved the VEGFR2 locus at the expected site in MVECs. To find potential off-targets for the mK22-targeted genes, the “CRISPR Design Tool” (http://crispr.mit.edu/) was used. NGS analysis indicated that mK22 did not influence on the most possible off-target sequence in MVECs. Western blot analysis of the transduced cell lysates indicated that there was an 80% decrease in VEGFR2 from the transduced MVECs with SpCas9/mK22 compared with those with SpCas9/lacZ (Fig. 1f), demonstrating that the AAV–CRISPR/Cas9 system with mK22 efficiently and specifically induced mutations within the VEGFR2 locus and subsequent protein depletion in MVECs in vitro.

Transduction of ECs with rAAV1 in vivo. Gene delivery to the vasculature has significant potential as a therapeutic strategy for several cardiovascular disorders including atherosclerosis and angiogenesis. However, there is a pronounced challenge in achieving successful gene transfer in vascular ECs in vivo. To determine if rAAV1 was capable of transducing vascular ECs of NV in the C57BL/6 mouse models of OIR and laser-induced CNV, we intravitreally injected rAAV1-CMV-GFP into mouse eyes at postnatal day 12 (P12) with or without experiencing the OIR model and immediately after the post-laser injury to Bruch’s membranes of six-week-old mice in the CNV model, respectively. Whole-mount retinas of the P17 mouse from the OIR model and the whole-mount choroid of the mice at day 7 after injection from the CNV model were stained with mouse endothelial-specific marker isoelectric 4 (IB4)-Alexa 594. The merged images of IB4 with GFP indicated that rAAV1 was able to transduce normal vascular ECs in the retinal (Supplementary Fig. 1) and that preferentially transduced vascular ECs of NV induced by hypoxia and laser injury in the OIR (Fig. 2 and Supplementary Figs. 2 and 3) and CNV models (Fig. 2 and Supplementary Fig. 4), respectively.

Editing genomic VEGFR2 abrogated hypoxia-induced angiogenesis. To investigate whether the dual AAV system of AAV-SpCas9 and AAV-SpGuide (mK22) was able to edit VEGFR2 and inhibit pathological angiogenesis in vivo, we intravitreally injected equal amount of rAAV1-SpCas9 and rAAV1-mK22 or rAAV1-lacZ into P12 mouse eyes in the OIR mouse model. In this model, P7 mouse pups with nursing mothers are subjected to hyperoxia (75% oxygen) for 5 days, which inhibits retinal vessel growth and causes significant vessel loss. On P12, mice are...
returned to room air and the hypoxic avascular retina triggers both normal vessel regrowth and retinal NV named as preretinal tufts, which is maximal at P17 23. Thus, on P17, the whole-mount retinas were stained with IB4. The results (Fig. 3a – c and Supplementary Fig. 5) showed that there was a dramatic decrease in the number of preretinal tufts and significantly more avascular areas from mice injected with rAAV1-SpCas9/mK22 than those with rAAV1-SpCas9/lacZ, suggesting that genome editing of VEGFR2 by SpCas9/mK22 inhibits retinal NV in this OIR mouse model. Next-generation sequencing results (Fig. 3d) confirmed that there was about 2% insertion/deletions (indels) around the PAM from genomic DNA of the retinas treated with AAV-SpCas9/mK22, but none with AAV-SpCas9/lacZ. In addition, western blot analysis of the retinal lysates showed that there was an about 30% reduction in VEGFR2 from mice treated with rAAV1-SpCas9/mK22 compared with controls (Fig. 3e, f). Taken together, these data demonstrate that editing genomic VEGFR2 locus with SpCas9/mK22 abrogates hypoxia-induced angiogenesis in this OIR mouse model. In addition, the intravitreal injection of SpCas9/mK22 did not cause detectable damage to the retina morphology and function examined by optical coherence tomography (OCT), electrotoretinography (ERG), fluorescein fundus angiography (FFA), and whole-mounted retina staining by IB4 at the time point of 4 weeks (Supplementary Fig. 6).

Fig. 1 AAV-CRISPR/Cas9-mediated depletion of VEGFR2 in vitro. a Schematic of AAV-SpGuide (V1) 15. Graphical representation of the mouse VEGFR2-targeted locus. The oligos of mK22 and its compliment were annealed and cloned into the V1 vector by SapI. The PAM is marked in blue. ITR inverted terminal repeat, U6 a promoter of polymerase III, CMV a promoter of cytomegalovirus, GFP green fluorescent protein. b Schematic of AAV-SpCas9 (V3). pMecp2: a neuron-specific promoter for methyl CpG-binding protein in V0 was substituted for pICAM2 19 by XbaI/AgeI. c Transduction of cultured cells with rAAV1. HRECs, HUVECs, and hPRPE cells in a 48-well plate to 50% confluence were infected with rAAV1-CMV-GFP (2 μl/well, 3.75 × 10^12 viral genome-containing particles (vg)/ml). Three days later, the cells were photographed under an immunofluorescence microscope. Three independent experiments showed rAAV1 transduction efficiency in HRECs, HUVECs and hPRPE cells of 85.6 ± 2.2, 88.5 ± 2.3 and 86.8 ± 2.6%, respectively. Scale bar: 200 μm. d pICAM2-driven expression of SpCas9 in ECs. After transduction with rAAV1-CMV-GFP (GFP) or rAAV1-pICAM2-SpCas9 (SpCas9) (2 μl/well, 3.75 × 10^12vg/ml) in a 48-well plate for 4 days, cell lysates were subjected to western blot analysis with antibodies against Cas9 and β-actin. Data shown are representative of three independent experiments. e Sanger DNA sequencing was conducted on PCR products amplified from the genomic VEGFR2 loci of MVECs, which were transduced by rAAV1-SpCas9 plus rAAV1-lacZ (lacZ) or rAAV1-mK22 (mK22). f Depletion of VEGFR2 expression using AAV-CRISPR/Cas9. Total cell lysates from the transduced MVECs were subjected to western blot analysis with antibodies against VEGFR2 and β-actin. The bar graphs are mean ± SD of three independent experiments. * * * indicates a significant difference between the compared two groups using an unpaired t-test. p < 0.05.
VEGFR2 suppressed NV in laser-induced CNV in mice. We also assessed whether the rAAV1-SpCas9/mK22 could inhibit NV in the laser-injury-induced CNV mouse model, which has been used extensively in studies of the exudative form of human AMD.24 First, we intravitreally injected rAAV1-SpCas9 with rAAV1-mK22 or rAAV1-lacZ into mouse eyes following the laser injury. In this model, NV grows from choroid vessels after laser injury on Bruch’s membrane, and on day 7 there is the maximal CNV, which begins to regress spontaneously after 14–21 days.24,31 Hence, on day 7, fluorescein was injected into the mice intraperitoneally, and images of fluorescein angiography (FA) were taken. Subsequently, the flat-mount choroids were stained by IB4 for analysis of laser-injury-induced CNV. As shown in Fig. 4a–c, there was less NV in the eyes injected with rAAV1-SpCas9/mK22 than those with rAAV1-SpCas9/lacZ on day 7.

To examine if editing genomic VEGFR2 could promote regression of CNV, rAAV1s were intravitreally injected on day 7 in the mouse CNV. On day 14, the images of FA and IB4 staining showed that there was less CNV from the mice injected with rAAV1-SpCas9/mK22 than those with rAAV1-SpCas9/lacZ (Fig. 4d–f). These data indicate that editing the genomic VEGFR2 locus with SpCas9/mK22 suppresses NV in this laser-injury-induced CNV model. Taken together, our data establish a strong foundation for genome editing as a novel therapeutic approach to angiogenesis-associated diseases.

Discussion
We report that rAAV1 preferentially transduced vascular ECs of pathological vessels in both mouse models of OIR and laser-injury induced CNV (Fig. 2 and Supplementary Fig. 3) while also transducing normal vascular ECs in the retina (Supplementary Fig. 1). The preferential transduction of ECs in pathological vessels may be due to the fact the neovessels are less mature than normal vessels, and have incomplete basement membrane and weaker intercellular junctions. To date, AAV vectors have been used in a number of clinical trials such as for Leber’s congenital amaurosis25–27 and congestive heart failure28 and has been approved for treatment of lipoprotein lipase deficiency in Europe29,30. While anti-VEGF agents (e.g., ranibizumab and aflibercept) can reduce NV growth and vascular leakage-associated eye diseases (e.g., PDR and wet AMD), therapeutic challenges remain, including the need for chronic treatment and a significant number of patients who do not respond31; gene therapy targeting genomic VEGFR2 using AAV-CRISPR/Cas9 may provide a novel alternative approach. While other genes, such as MMP931,32, have been linked to various proliferative retinopathies, none has been shown to drive new vessel disease to the extent seen VEGFR2.

Success translation of genome editing technologies to the clinic must address some major obstacles, primarily in terms of the safety and efficacy; genetic modifications are permanent, and deleterious off-target mutations could create cells with oncogenic potential, reduced cellular integrity, and or functional impairments.33,34 Our results demonstrate that expression of VEGFR2 was depleted by 80% in vitro (MVEC) (Fig. 1) and by 30% in vivo (retina) (Fig. 3) by the AAV-CRISPR/Cas9 (mK22), in which SpCas9 was driven by an endothelial cell-specific promoter pICAM2 (Fig. 1). In addition, NGS analysis indicated that there was only about 2% indels around the PAM in the PCR products amplified from the treated P17 mouse retinas, and there was a significant decrease in NV in both mouse models of OIR (Fig. 3) and CNV (Fig. 4) after treatment with AAV-CRISPR–Cas9-targeting genomic VEGFR2 in comparison to targeting control lacZ.
The lysates of the rAAV1-SpCas9/lacZ or -mK22-injected retinas were subjected to western blot analysis using indicated antibodies. The bar graph data ± indicates significant difference using an unpaired t-test. *p < 0.05

In summary, our studies show that precise and efficient gene editing of VEGFR2 using CRISPR–Cas9 systems has the potential to treat angiogenesis-associated diseases.

Methods

Mice. Six–eight-week-old mice (C57BL/6J, male and female) were purchased from Jackson Laboratories (Bar Harbor, ME). All the animal experiments followed the guidelines of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. There were at least three experiments for statistic analyses and investigators who conducted analysis were masked as to the treatment groups. All the mice were cared for by following the ACUC protocol approved by the Institutional Animal Care and Use Committee at Schepsen Eye Research Institute.

Major reagents. Antibodies against VEGFR2 (1:1000 for western blot) and β-actin (1:5000 for western blot) were purchased from Cell Signaling Technology (Danvers, MA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:5000) and anti-mouse IgG (1:5000) were from Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescent substrate for detection of HRP was from ThermoFisher Scientific (Waltham, MA). Alexa fluorescence-594-conjugated mouse endothelial-specific isocititin B4 (IB4) was purchased from Life Technology (Grand Island, NY). The plasmids of pAAV-pMecp2 SpCas9-spA (AAV-SpCas9) (cat. no. 60,957) and pAAV-U6-sgRNA(Spapl)-hSyn-GFP-KASH-bGH (spGuide acceptor) (cat. no. 60,958) were purchased from Addgene (Cambridge, MA). High-fidelity Herculase II DNA polymerases were from Agilent Technologies (Santa Clara, CA).

Cell culture. C57BL/6 mouse primary brain microvascular endothelial cells (MVECs) were purchased from CellBiology (cat. no. C57-C57-6023, Chicago, IL) and cultured in the endothelial cell medium with a kit (CellBiology). Human primary retinal microvascular endothelial cells (HRECs) were purchased from Cell Systems (cat. no. ACRB1 181V, Kirkland, WA) and cultured in endothelial growth medium-2 (Lonza, Walkersville, MD). Primary human umbilical vein endothelial cells (HUVECs, cat. no. CC-2517) and human primary retinal pigment epithelial cells (hPRPE, cat. no. 194987) were purchased from Lonza. HUVECs were cultured in Medium 199 (Sigma) supplemented with 20% bovine calf serum (HyClone, Logan, UT), 100 mg/ml heparin, 12 mg/ml bovine brain extract (Hammond Cell Tech, Windsor, CA). hPRPE cells were cultured in a 1:1 mixture of low-glucose Dulbecco’s modified Eagle’s medium (Life Technologies, Grand Island, NY) and Ham’s F-12 Nutrient Mixture (Gibco) supplemented with 10% fetal bovine serum (Lonza, Walkersville, MD). Tissue culture dishes were precoated with 2% gelatin in phosphate-buffered saline for MVECs, HRECs, and HUVECs. All cells were cultured at 37 °C in a humidified 5% CO₂ atmosphere.

DNA constructs. The 20 nt target DNA sequence (5′-GTCCCGGTGACAGCCACTTGTAGGCTCC-3′, mK22) preceding a 5′-NGG PAM sequence at exon 3 in the mouse VEGFR2 genomic locus (NC_000071.6) was selected for generating single guide RNA (gRNA) for SpCas9 using the CRISPR design tool. The control gRNA sequence (5′-TGCCGACTAAGCGCCAGCGGATGG-3′) was designed to target the lacZ gene of Escherichia coli. The PAAV-U6-sgRNA-CMV-GFP vector (V1) was originated from AAV-SpCas9 (cat. no. 60,958) by replacing the hSyn-GFP with the PCR-amplified CMV-GFP from pEGFP-C1 vector (Clontech, cat. no. 6084-1) using Xbal/EcoRI as described previously. The pAAV-pICAM2-SpCas9 (V3) was derived from AAV-SpGuide (cat. no. 60,957) by replacement of the promoter pMeP2 using XbaI/AgeI with plPCAM2, which was PCR amplified from genomic DNA isolated from HRECs. The PCR primers for this amplification were: forward 5′-CTGTCTAGATCTAAAGCGCTGTGGCTACGTC-3′, reverse 5′-GGACAGGCCAAGAGGGTGCGAGGAG-3′. All these constructs were confirmed by DNA sequencing.

To construct SpGuides, the top oligo 5′-AAC-GTCGCCGTGACAGCCACTTGTAGGCTCC-3′ and bottom oligo 5′-AAC-20nt-C-3′ (20 nt: complimentary target mK22 DNA sequences) were annealed and cloned into the V3 vector by SapI. All clones were confirmed by DNA sequencing using a primer 5′-GGACACTATCATATGCTTAACGG-3′ from the sequence of U6 promoter, which drives expression of sgRNAs. Both synthesis of primers and oligos and sequencing of PCR products and clones were done by Massachusetts General Hospital (MGH) DNA Core Facility (Cambridge, MA).

Production of AAVs. The recombinant AAV2/1 (rAAV1) vectors were produced as described previously in the Gene Transfer Vector Core in Scheeps Eye Research Institute of Massachusetts Eye and Ear (Boston, MA). Briefly, triple transfection of AAV package plasmid (AAV2/1), transgene plasmid (pAAV-pICAM2-SpCas9: AAV-SpCas9, pAAV-U6-mK22-CMV-GFP: AAV-mK22 or pAAV-U6-lacZ-CMV-GFP: AAV-lacZ) and adenosine helper plasmid were performed in a 10-layer hyper flask containing confluent HEK 293 cells. At day 3 post transfection, the cells and culture medium were collected and enzymatically treated with Benzonase (EMD Millipore). After high-speed centrifugation and filtration, the cell debris was cleared. The viral solution was concentrated by running through tangential flow filtration, and then loaded onto an iodixial gradient column. After one round of ultracentrifugation, the pure vectors were separated and extracted, then ran through an Amicon Ultra-Centrifugal Filter device (EMD Millipore) for desalting. Both vectors were titrated by TaqMan PCR amplification (Applied Biosystems 7500, Life Technologies), with the primers and probes detecting the transgene. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to check the purity of the vectors, which were named rAAV1-SpCas9, rAAV1-mK22, and rAAV1-lacZ.

Transduction of cultured cells. MVECs, HRECs, HUVECs, and hPRPE cells grown to 50% confluence in a 48-well plate were changed into the fresh cultured media and added either with rAAV1-mK22, rAAV1-lacZ, rAAV1-SpCas9...
individually or both of rAAV1-SpCas9 with rAAV1-mK22 or rAAV1-lacZ (2 μl/well for each rAAV1, 3.75 × 10¹² viral genome-containing particles (vg)/ml). Three days later, the cells were photographed under an immunofluorescence microscope for determining the rAAV1 transduction efficiency. After 4 days, the cells were lysed with 1× sample buffer for western blotting analysis or collected for genomic DNA isolation.

Western blot. Cells were lysed in 1× sample buffer, which was diluted with extraction buffer (10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1% Triton X-100, 20 μg/ml aprotinin, 2 mM Na₃VO₄, and 1 mM phenylmethylsulfonyl fluoride) from the 5× protein sample buffer (25 mM EDTA (pH = 7.0), 10% sodium dodecyl sulfate (SDS), 500 mM dithiothreitol, 50% sucrose, 500 mM Tris-HCl (pH = 6.8), and 0.5% bromophenol blue). The lysates were boiled for 5 min and then centrifuged for 5 min at 13,000 × g. Proteins from the samples were separated by 10% SDS-PAGE, transferred to polyvinylidene fluoride membranes, and subjected to western blot analysis. Experiments were repeated at least three times. Signal intensity was determined by densitometry using NIH ImageJ software.

DNA sequencing. Cells were collected for genomic DNA extraction using the QuickExtract DNA Extraction Solution (Epicenter, Chicago, IL), following the manufacturer’s protocol. In brief, the pelleted cells were re-suspended in the

Fig. 4 AAV-CRISPR/Cas9-targeting genomic VEGFR2 suppressed NV in laser-induced choroid NV in mice. After laser injury of Bruch’s membrane, fundus images (day 0) were taken using the Micron III system, and the mice were injected intravitreally with 1 μl (3.75 × 10¹² vg/ml) containing equal rAAV1-SpCas9 and rAAV1-lacZ or -mK22 right immediately after the laser injury (a) or 7 days of the laser injury (d). Seven days after AAV1 injection, the mice were injected intraperitoneally with fluorescein, and the FA images were taken using the Micron III system. Subsequently, whole mounts of choroids were stained with IB4, and the images were taken under an immunofluorescence microscope. Areas of NV were analyzed based on the images of FA (b, e) and IB staining (c, f) (n = 6). * indicates significant difference between the compare two groups using an unpaired t-test, p < 0.05.
Killed, and the mouse eyes were carefully removed and fixed in 3.7% PFA. Whole Retinal sections were stained overnight at 4 °C with murine-anti-CD31 (1:100 dilution in PBS) followed by Alexa 488-coupled anti-mouse (1:100 dilution in PBS) for the OIR model. Retinal whole mounts were stained overnight at 4 °C with murine-anti-CD31 (1:100 dilution in PBS) followed by Alexa 488-coupled antirabbit (1:100 dilution in PBS) for the AV/CRISP model.

DNA sequencing was performed by the MGH DNA core facility.

This OIR model. Retinal whole mounts were stained overnight at 4 °C with murine-specific EC marker isolectin 4 (IB4)-Alexa 594 (red)23,38,39. The images were taken with an EVOS FL Auto microscope (Life Technologies).

Quantification of vaso-obliteration and NV. This was performed previously23,25. Briefly, retinal image was imported into Adobe Photoshop CS4, and the Polygonal Lasso tool was applied to the avascular area. One number of pixels in the avascular area was highlighted, the number of pixels was obtained. After selecting total retinal area, the Lasso tool and the “subtract from selection” icon was used to selectively remove the vascularized retina, leaving behind only the avascular area. Once the avascular region was selected, click the refresh icon again to obtain the number of pixels in the avascular area.

When analyzing NV, the original image was opened. The magic wand tool was selected from the side tool panel on the left side of the screen. On the top tool panel, the tolerance to a level that will pick up NV was set while excluding normal vessels (beginning at 50). Regions of NV were selected by clicking on them with the magic wand tool. The areas of NV fluoresced more intensely than surrounding normal vessels. When neovessels were selected, the area of interest was zoomed in by holding the “Alt” key on the keyboard and scrolling up. When all NV was selected and checked, the refresh icon recorded the total number of pixels clicked in the NV area.

Laser-induced choroid NV in mice. Ten mice (Stock number: 664, C57BL/6, male and female, 17–22 g, 6–8 weeks old, Jackson Laboratories, Bar Harbor, ME) were divided into two groups with an intraperitoneal injection of ketamine/xylazine (120 mg/kg ketamine/20 mg/kg xylazine). Their pupils were dilated by using a drop of 1% tropicamide followed by a drop of 1% cyclopentolate hydrochloride applied on the corneal surface. One drop of Gentec (corneal lubricant) was applied to the cornea of the untreated eye to prevent dehydration. A 0.9% sterile saline solution was applied on the cornea of the treated eye to prevent dehydration and to allow electrical contact with the recording electrode (gold wire loop). A 25-gauge platinum needle, inserted subcutaneously in the forehead, served as reference electrode, while a needle inserted subcutaneously near the tail served as the ground electrode. A series of flash intensities was produced by a Ganzfeld controlled by the Diagnosys Espion 3 to test both scotopic and photopic response.

The following day after ERG, FFA was performed on the mice. Animals were anesthetized with a mixture of ketamine (100–200 mg/kg) and xylazine (20 mg/kg), and their pupils were dilated using a drop of 1% tropicamide and the eye will be treated with topical anesthesia (Proparacaine drops). A drop of sterile saline was applied on the eye before injection to remove any debris followed by Gentec. Gentec was placed on both eyes to prevent corneal drying. Then 0.01 ml of 25% sodium fluorescein (pharmaceutical grade sodium fluorescein; Akorn Inc) 5 g body weight was injected i.p. The retinal vasculature was filled with dye in <1 min following injection. Photos were taken sequentially at 1, 2, 3, 4, and 5 min post-fluorescein injection. A Micron III (Phoenix Research) system was used for taking fundus photographs according to the manufacturer’s instructions. The mice were placed in front of the Fundus camera and pictures of the retina taken above for monitoring retinal function.

The mice were killed, retinas were carefully removed and fixed in 3.7% PFA. Retinal whole mounts were stained overnight at 4 °C with murine-specific EC marker isolectin 4 (IB4)-Alexa 594 (red)23,38,39. The images were taken with an EVOS FL Auto microscope (Life Technologies).

Statistics. The data from three independent experiments in which the variance was similar was grouped between the studies analyzed using an unpaired and two-tailed t-test. For animal experiments, at least the data from six mice were used for the t-test. For animal experiments, at least the data from six mice were used for the statistic analysis. p-values of <0.05 were considered statistically significant. All relevant data are available from the authors.

Data availability. The data supporting the findings of this study are available from the corresponding author on reasonable request.

Received: 29 November 2016 Accepted: 5 June 2017
Published online: 24 July 2017

References
1. Sengör, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1982).
2. Sengör, D. R. et al. Hypoxia-induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. 1, 182–193 (1995).
3. Muller, Y. A. et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA 94, 7192–7197 (1997).
4. Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 19, 2003–2012 (2007).
5. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995).
6. Williams, R. et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18, 963–983 (2004).
7. Fraser-Bell, S., Kaives, A. & Hykin, P. G. Update on treatments for diabetic macular edema. Curr. Opin. Ophthalmol. 19, 185–189 (2008).
8. Mintz-Hittner, H. A., Kennedy, K. A., Chuang, A. Z. & Group, B.-C. Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity. N. Engl. J. Med. 364, 603–611 (2011).
9. Stahl, A. et al. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 57, 8813–8826 (2016).
10. Chakravarthy, U. et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382, 1258–1267 (2013).
11. Suzuki, M. et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br. J. Ophthalmol. 98, 1186–1191 (2014).
12. Deyle, D. R. & Russell, D. W. Adeno-associated virus vector integration. Curr. Opin. Mol. Ther. 11, 442–447 (2009).
13. Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108–112 (2016).
14. Jin, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
15. Duan, Y. et al. The clustered, regularly interspaced, short palindromic repeats-associated endonuclease 9 (CRISPR/Cas9)-created MDM2 T370G mutation enhances vitreous-induced expression of MDM2 and proliferation and survival of cells. J. Biol. Chem. 291, 16339–16347 (2016).
16. Swierz, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102–106 (2015).
17. Tabeobdbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).
18. Chitranshi, N., Gupta, V., Kumar, S. & Graham, S. L. Exploring the molecular interactions of 7,8-Dihydroxyavone and Its derivatives with TrkB and VEGF2 proteins. Int. J. Mol. Sci. 16, 21087–21108 (2015).
19. Dai, C., McNamnch, R. E. & Sutton, R. E. Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen. J. Virol. 78, 6209–6221 (2004).
20. Ellis, B. L. et al. A survey of ex vivo/in vitro transduction efficiency of adeno-associated viral vectors. Nat. Protoc. 1, 16339–16347 (2015).
21. Gaudet, D., Methot, J. & Kastelein, J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23, 310–320 (2012).
22. Gaudet, D., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal. 19, 2003–2012 (2007).
23. Connor, K. M. et al. Quantiﬁcation of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565–1573 (2009).
24. Lambert, V. et al. Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat. Protoc. 8, 2197–2211 (2013).
25. Maguire, A. M. et al. Safety and efficacy of gene transfer for leber’s congenital amaurosis. N. Engl. J. Med. 358, 2240–2248 (2008).
26. Bainbridge, J. W. et al. Effect of gene therapy on visual function in leber’s congenital amaurosis. N. Engl. J. Med. 358, 2231–2239 (2008).
27. Hauswirth, W. W. et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979–990 (2008).
28. Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intraocular gene therapy of sarcoplasmic reticulum Ca2+ -ATPase in patients with advanced heart failure. Circulation 124, 304–313 (2011).
29. Gaudet, D., Methot, J. & Kastelein, J. Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23, 310–320 (2012).
30. Gaudet, D. et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20, 361–369 (2013).
31. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744 (2000).
32. Giraudou, E., Inoue, M. & Hanahan, D. An amino-biphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114, 623–633 (2004).
33. Zhang, F. CRISPR-Cas9: prospects and challenges. Hum. Gene Ther. 26, 409–410 (2015).
34. Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).
35. Ruan, G. X. & Kazlauskas, A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 31, 1692–1703 (2012).
36. Lei, H. et al. RasGAP promotes autophagy and thereby suppresses platelet-derived growth factor receptor-mediated signaling events, cellular responses, and pathology. Med. Cell. Biol. 35, 1673–1685 (2015).
37. Saint-Geneix, M. et al. PGC-1alpha regulates normal and pathological angiogenesis in the retina. Am. J. Pathol. 182, 255–263 (2013).
38. Wei, H. et al. Alternative treatments to inhibit VEGF in age-related macular degeneration. Br. J. Ophthalmol. 98, 1186–1191 (2014).
39. Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108–112 (2016).
40. Giana, A. et al. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 52, 3880–3887 (2011).

Acknowledgements
This work was supported by National Institutes of Health, National Eye Institute Grants R01 EY102590 (to H.L.) and Core Grant P30EY003790.

Author contributions
X.H., G.Z., W.W., Y.D., G.M. and J.S. performed most of the experiments and analyzed the results. R.X. and I.V. contributed to production of AAVs. F.Z. contributed to experimental design and P.D.A. revised the manuscript. H.L. designed and performed experiments, analyzed the results, and wrote the manuscript.

Additional information
Supplementary Information accompanies this paper at doi: 10.1038/s41467-017-00140-3.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://www.nature.com/reprintsandpermissions/

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017